We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Increased Hormones Lead to Idiopathic Intracranial Hypertension

By LabMedica International staff writers
Posted on 02 Apr 2019
Print article
Image: Fundus appearance for a woman with Idiopathic Intracranial Hypertension (IIH), showing severe papilledema in the right eye (A) and moderate papilledema in the left eye (B) (Photo courtesy of Devin K. Binder MD, PhD, and colleagues).
Image: Fundus appearance for a woman with Idiopathic Intracranial Hypertension (IIH), showing severe papilledema in the right eye (A) and moderate papilledema in the left eye (B) (Photo courtesy of Devin K. Binder MD, PhD, and colleagues).
Idiopathic Intracranial Hypertension, also known as IIH, is caused by high pressure in the brain with consequences from blindness to incapacitating daily long-term headaches. Patients have reduced quality of life due to chronic headaches and papilledema-induced visual loss which is permanent in 25% of patients.

Once regarded as rare, incidence of IIH is now rising dramatically in line with the global rise in obesity and there has been a 150% rise in incidence in the last 10 years. Currently there are very limited treatment options. IIH shares phenotypic characteristics with polycystic ovary syndrome (PCOS), in which androgen excess is a defining feature.

A team of scientists collaborating with the University of Birmingham (Birmingham, UK) examined the levels of androgens in blood and urine, as well as in brain fluid known as cerebrospinal fluid (CSF), in 55 women with IIH aged 18 to 45. They then compared the results with the levels observed in women with obesity of the same age and body mass index (BMI), as well as a cohort of women with PCOS. Analysis of live cell data was acquired with MetaMorph. An image sequence was initially analyzed on ImageJ (V1.48; National Institute of Health, Bethesda, MD, USA), where individual random cells are selected as a region of interest and motile cells are excluded from the analysis.

The team found that found that IIH patients had a very different profile of raised levels of androgens compared to women of a similar age with obesity and women with PCOS. Most notable were the high levels of the androgen testosterone, which is found in the blood in IIH women. Crucially, levels of androgens were uniquely increased in the brain fluid (CSF) of women with IIH. When they, analyzed human choroidal plexus tissue, which is the site in the brain where CSF is produced, they confirmed that androgens could increase the rate of CSF secretion, a potential driver for increased brain pressure.

The authors concluded that women with IIH have a distinct androgen excess signature, which, with the in vitro assay on Na+/K+-ATPase activity, supports a potential role for androgens in the pathogenesis of IIH. They proposed that potent androgens are activated in the choroid plexus and/or cross the blood-brain barrier after activation in other tissues where they affect CSF secretion and intracranial pressure (ICP).

Alexandra J. Sinclair MBChB, MRCP, PhD, a clinical scientist and senior author of the study said, “These findings mark a key step forward; for the first time we have found a pattern of androgen dysregulation that is unique to IIH and potentially a driver of abnormal brain pressure in people with the condition. Taken together this provides the first evidence that IIH may be a manifestation of female androgen excess.” The study was published on March 21, 2019, in the journal JCI Insight.

Related Links:
University of Birmingham
National Institute of Health

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more